Incyte (INCY) Misses Q1 EPS by 1c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/25/2026

1. DECK
2. RNG
3. WDC
4. BMY
5. BYD
6. WCN
7. SPOT
8. SPY
9. FIX
10. TSCO

Go back to Incyte (INCY) Misses Q1 EPS by 1c

Incyte Reports 2015 First-Quarter Financial Results and Updates Shareholders on Key Clinical Programs

April 30, 2015 7:00 AM EDT

$115 million of 2015 first-quarter net product revenues from Jakafi® (ruxolitinib), representing 66 percent growth over the same period last year $25 million milestone received from Novartis related to the approval of Jakavi® (ruxolitinib) for polycythemia vera in Europe; $16 million product royalties from sales of Jakavi, representing 60 percent growth over the same period last year Primary endpoint met in second Phase III trial of baricitinib in rheumatoid arthritis; additional data disclosures expected during 2015 Recruitment continuing across clinical development portfolio in multiple pivotal and proof-of-concept... More